Plakous Therapeutics extends research through agreement with Mayo Clinic.
Plakous received award notice from NIH on a $1.7 Million Fast-Track SBIR grant to develop product for NEC.
Plakous Therapeutics, Inc is pleased to announce that they have received Orphan Drug and Rare Pediatric Disease designations from the FDA for their lead indication, NEC.
Plakous Therapeutics was selected to present on the main stage at the 2020 Venture Connect Summit in Raleigh, NC.
Plakous was selected as an Early Stage Presenter at the November 2019 SEBio Investor and Partnering Forum in Miami, FL.
Plakous was selected as an Global Innovation Challenge Finalist at the September 2018 RESI Boston meeting.
Get in Touch
Get the latest on business and research information.